中华生物医学工程杂志
中華生物醫學工程雜誌
중화생물의학공정잡지
CHINESE JOURNAL OF BIOMEDICAL ENGINEERING
2012年
3期
209-212
,共4页
张丽杰%赵振军%尹乃宁%冯忠军%鹿刚%王香玲%单保恩
張麗傑%趙振軍%尹迺寧%馮忠軍%鹿剛%王香玲%單保恩
장려걸%조진군%윤내저%풍충군%록강%왕향령%단보은
肝肿瘤%RNA干扰%Stat5转录因子%细胞凋亡
肝腫瘤%RNA榦擾%Stat5轉錄因子%細胞凋亡
간종류%RNA간우%Stat5전록인자%세포조망
Liverneoplasme%RNAinterference%Stat5 transcription factor%Apoptosis
目的 探讨Stat5-shRNA对裸鼠体内人肝癌SMMC7721移植瘤的抑制及其诱导肿瘤细胞凋亡的作用.方法 将SMMC7721细胞悬液接种于裸鼠背部皮下,15d后,待在接种部位出现肿瘤结节、质地较硬等指标认定为成瘤.将15只成瘤裸鼠完全随机分为:空白对照组、HK质粒对照组、Stat5-shRNA组共3组,每组各5只.空白对照组瘤内注射生理盐水,HK质粒对照组瘤内注射Pgenesil1-HK,Stat5-shRNA组瘤内注射Pgenesil-1 -Stat5A1,各组注射剂量及次数均为50μl/只,每2天1次,共10次.第35天,处死各组全部动物,剥瘤称重,计算肿瘤大小及抑瘤率,流式细胞术检测肿瘤细胞凋亡情况.结果 与空白对照组和HK质粒对照组比较,Stat5-shRNA组裸鼠人肝癌移植瘤的生长受到明显抑制,肿瘤细胞凋亡率明显上升[(21.35±3.69)%比(3.56±1.12)%,(3.81±3.05)%,P<0.05].结论 Stat5-shRNA可有效抑制裸鼠体内人肝癌移植瘤的生长,并能够诱导肿瘤细胞凋亡.Stat5-shRNA在人肝癌的基因治疗中具有潜在的应用价值.
目的 探討Stat5-shRNA對裸鼠體內人肝癌SMMC7721移植瘤的抑製及其誘導腫瘤細胞凋亡的作用.方法 將SMMC7721細胞懸液接種于裸鼠揹部皮下,15d後,待在接種部位齣現腫瘤結節、質地較硬等指標認定為成瘤.將15隻成瘤裸鼠完全隨機分為:空白對照組、HK質粒對照組、Stat5-shRNA組共3組,每組各5隻.空白對照組瘤內註射生理鹽水,HK質粒對照組瘤內註射Pgenesil1-HK,Stat5-shRNA組瘤內註射Pgenesil-1 -Stat5A1,各組註射劑量及次數均為50μl/隻,每2天1次,共10次.第35天,處死各組全部動物,剝瘤稱重,計算腫瘤大小及抑瘤率,流式細胞術檢測腫瘤細胞凋亡情況.結果 與空白對照組和HK質粒對照組比較,Stat5-shRNA組裸鼠人肝癌移植瘤的生長受到明顯抑製,腫瘤細胞凋亡率明顯上升[(21.35±3.69)%比(3.56±1.12)%,(3.81±3.05)%,P<0.05].結論 Stat5-shRNA可有效抑製裸鼠體內人肝癌移植瘤的生長,併能夠誘導腫瘤細胞凋亡.Stat5-shRNA在人肝癌的基因治療中具有潛在的應用價值.
목적 탐토Stat5-shRNA대라서체내인간암SMMC7721이식류적억제급기유도종류세포조망적작용.방법 장SMMC7721세포현액접충우라서배부피하,15d후,대재접충부위출현종류결절、질지교경등지표인정위성류.장15지성류라서완전수궤분위:공백대조조、HK질립대조조、Stat5-shRNA조공3조,매조각5지.공백대조조류내주사생리염수,HK질립대조조류내주사Pgenesil1-HK,Stat5-shRNA조류내주사Pgenesil-1 -Stat5A1,각조주사제량급차수균위50μl/지,매2천1차,공10차.제35천,처사각조전부동물,박류칭중,계산종류대소급억류솔,류식세포술검측종류세포조망정황.결과 여공백대조조화HK질립대조조비교,Stat5-shRNA조라서인간암이식류적생장수도명현억제,종류세포조망솔명현상승[(21.35±3.69)%비(3.56±1.12)%,(3.81±3.05)%,P<0.05].결론 Stat5-shRNA가유효억제라서체내인간암이식류적생장,병능구유도종류세포조망.Stat5-shRNA재인간암적기인치료중구유잠재적응용개치.
Objective To investigate the effcet of Stat5- shRNA on inhibition of human hepatocellular carcinoma (HCC) SMMC7721 xenograft and induction of tumor apoptosis in nude mice.Methods SMMC7721 cell suspension solution was inoculated subcutaneously into the flank of nude mice.Tumor was identified based on existence of nodules or hardened texture at the site of inoculation at day 15 and thereafter.A cohort of 15 tumor-loaded nude mice were then randomly divided into blank control(n=5),HK plasmid control (n=5) and Star5-shRNA group (n=5),respectively.The blank control group was intratumorally injected with normal salinc,HK plasmid control group with Pgenesil-l-HK,and Stat5-shRNA group with Pgenesil-1-Stat5A1,respectively,for 50 μl per mouse,once every other day with a total of 10 injections.At day 35,the mice were euthanized for hatvesting the tumors and computation of tmnor size and inhibition rate.While tumor apoptosis was examined via flow cytometry.Results Stat5-shRNA treatment resulted in markcd inhibition of tumor growth and mounted apoptosis rate (both P<0.05) on hmnan HCC xenograft in nude mice as compared with blank control and HK plasmid control group [ (21.35±3.69)% vs (3.56 ± 1.12)%,(3.81 ± 3.05)%,P<0.05].Conclusion Stat5 - shRNA is correlated with effective inhibition of human HCC xenograft and induction of tumor apoptosis in nude mice,suggesting the potential for gene therapy in patients with HCC.